Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01282320
Other study ID # REK2009/1429
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2011
Est. completion date December 2013

Study information

Verified date July 2013
Source University Hospital of North Norway
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

More than 60 % of women experience hot-flashes during postmenopausal and 20 % have serious symptoms. Use of combined estrogen/progesterone therapy reduces hot-flashes effectively. In 2001, results from the randomized controlled WHI-study (Womens Health Initiative) showed increased risk for breast cancer and hearth-disease among users of combined estrogen/progesterone therapy. This reduced the use of combined estrogen/progesterone therapy. Many women seek alternative treatment for hot-flashes. They are often told that physical activity can reduce intensity and frequency of hot-flashes. The evidence for this advice is sparse.

The primary hypothesis tested in the WHAT-study will be: Increased physical activity reduce frequency and intensity of hot-flushes among sedentary postmenopausal women with bothersome hot-flushes.

The WHAT-study is designed as a pragmatic randomized controlled clinical trial. To answer the primary hypothesis we will need approximately 500 participants. The logistic in a pragmatic trial of a complex intervention are complicated and we decided to first run a pilot study with 50 participants as a feasibility study. The pilot gives us opportunity to gain experience with possible problems like withdrawals and injuries.


Description:

The WHAT study is a pragmatic randomized controlled trial with two parallel arms. The intervention is a 16 weeks individually tailored training programme with one hour physical activity 2-3 times per week. Women randomized to the control group are asked to keep physical activity at the same level as before the study.

Healthy postmenopausal women from Tromso will be recruited to the study by newspaper advertisements and media coverage. Interested women are asked to make a call. A staff member will ask about menopausal status, level of physical activity and diseases. Potential participants will receive a diary by mail and will be asked to record frequency and severity of hot-flashes, and duration of sleep at night for a period of 14 days. Women who return this diary will be asked to sign the informed consent and complete a questionnaire, before the fitness test. Baseline fitness is an important measure in this study. We will measure VO2-max (maximal oxygen consumption) as a proxy for fitness. Whether you are randomized to intervention or control group can influence the fitness test. The participants will therefore be randomized after the fitness test.

Randomization: Unit of Applied Clinical Research, Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, will develop and administrate a web-based randomization system for the WHAT pilot study. The data base will be located at a server at the Medical Faculty at Norwegian University of Science and Technology in Trondheim. The following staff are authorized to randomize people in WHAT pilot study: Sameline Grimsgaard, Merethe Kumle, Sissel Andersen , Jorid Degerstrøm, Svein Arne Pettersen

In this pilot 50 women will be randomized either to intervention group (25 women) or control group (25 women).

Elements in the intervention: A physiotherapist will based on interview and physical examination make a plan for the 16 weeks physical activity programme for each participant. The program will start with Pilates classes and low intensity aerobic training (2-4 weeks). After this period, classes with moderate to high intensity aerobic training will be introduced. The aim of the intervention is to increase aerobic capacity with 10 % from baseline.

Both the intervention group and the control group will receive questionnaires at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 6 months and 1 year after inclusion. We will run the test for physical fitness at baseline and 16 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 2013
Est. primary completion date March 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Postmenopausal

- Natural or induced menopause

- > 12 months since last menstruation

- Severe hot flushes (frequency and intensity)

- Sedentary life style

- Motivated to increase level of physical activity

Exclusion Criteria:

- Current use of estrogen/progesterone treatment.

- Physical active (mean activity last six months

- More than 30 min per regularly exercise sessions at least once a week.

- Regular exercise sessions are defined as any planned physical activity (e.g., brisk walking, aerobics, jogging, bicycling, swimming, rowing, etc.) performed to increase physical fitness. BMI > 35 kg/m2, disease of illness that can hamper regular training.

- Current use of HT (systemic or plaster) during last 8 weeks

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Physical activity intervention program
Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.

Locations

Country Name City State
Norway University Hospital of North Norway Tromsø Troms

Sponsors (2)

Lead Sponsor Collaborator
University Hospital of North Norway University of Tromso

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mean hot-flashes frequency and intensity (per 24/hours). Potential participants receive a diary by mail and are asked to record frequency and severity of hot flashes and duration of sleep at night for a period of 14 subsequent days. During the study period the participants record frequency and intensity of hot flashes and duration of sleep at night for a period of 7 subsequent days at 4, 8, 12, 16 weeks and 6 months and one year. Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks , 6 months and 1 year
Secondary Quality of life measured with Women's Health Questionnaire (WHQ) 23 items. We will measure quality of life with Women's Health Questionnaire. This is a self-administered questionnarie. A Norwegian version has been validated psychometric and linguistically. Baseline, 16 weeks, 6 months, one year.
Secondary Depressive symptoms are measured with Beck Depression Inventory -II (BDI-II) The Beck Depression Inventory - Second Edition (BDI-II; Beck et al., 1996) is a 21-item self-report inventory designed to assess the presence and severity of depressive symptoms and is rated on a four-point Likert-type scale ranging from 0 to 3, reflecting the severity of each item. The BDI-II scores are classified as following: 0-13 minimal; 14-19 mild; 20-28 moderate; and 29-63 severe (Beck et al., 1996). A full description of the inventory including psychometric properties can be found in Steer, Ball, Ranieri, and Beck (1999). Baseline, 16 weeks, 6 months
Secondary Dysfunctional attitudes related to cognitive vulnerability to depression. The Dysfunctional Attitude Scale (DAS)(Form A) (DAS; Weisman & Beck, 1978) is a 40-item self-report inventory to be rated along a seven-point Likert scale ranging from "totally agree" to "totally disagree", designed to assess the presence of dysfunctional attitudes that may relate to cognitive vulnerability to depression (Oliver & Baumgart, 1985). A full description including psychometric properties is provided by Chioqueta and Stiles (2004), Dobson and Breiter (1983) and Oliver and Baumgart (1985). Baseline, 16 weeks, 6 months
Secondary Increased physical fitness, measured as 10 % increase in VO2-max Physical fitness will be tested at the Regional Centre for Sport and Health, University of Tromsø, at baseline and after 16 weeks. VO2-max is used as a proxy for physical fitness. Baseline, 16 weeks
Secondary Motivation for change in physical activity - Stages of Change Permanent changes of behavior is difficult. We will use instruments from the Transtheoretical Model of Change, the Stages of Change short and long form to evaluate motivation for increased physical activity among the participants in the WHAT pilot study. The instrument might give valuable information about who a prone drop-out during study period. Baseline, 16 uker, 6 months and one year
Secondary Physical activity, motivation and experiences During the study period approximately 20 women (both from the intervention group and the control group) will be asked to participate i a qualitative study of physical activity, motivation and experiences. Betwen 2nd and 16th week
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04587154 - Womens Study to Alleviate Vasomotor Symptoms N/A
Terminated NCT03642119 - Validation of an Objective Instrument to Measure Hot Flashes During Menopause
Completed NCT05061563 - A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults Phase 1
Completed NCT05419908 - Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes Phase 2
Completed NCT01281332 - Mechanical Device for the Relief of Hot Flashes Phase 2
Completed NCT01439945 - Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer Phase 2
Completed NCT00755417 - Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women Phase 3
Completed NCT01293695 - Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial N/A
Completed NCT00599456 - Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women. N/A
Completed NCT00256685 - Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Phase 3
Completed NCT00391417 - Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms Phase 3
Terminated NCT00244894 - Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer N/A
Completed NCT00010712 - Effects of Black Cohosh on Menopausal Hot Flashes Phase 2
Active, not recruiting NCT03580499 - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy N/A
Recruiting NCT06030388 - Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women N/A
Recruiting NCT04418115 - Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option? N/A
Recruiting NCT04861701 - Effect and Predictors for Hot Flush in Women Undergoing Static Stretching Exercise N/A
Active, not recruiting NCT05086705 - EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer N/A
Completed NCT05099159 - A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2) Phase 3
Completed NCT01140646 - Evaluation of SAMe for Hot Flashes Phase 2